Semaglutide injection for the treatment of adults with type 2 diabetes

References

• Porte D, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001;50(Suppl 1):S160–S163.
   PubMedGoogle Scholar
• Saeedi P, Petersohn I, Salpea P, et al.. IDF diabetes atlas committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019Nov;157:107843. DOI:10.1016/j.diabres.2019.107843.
   PubMed Web of Science ®Google Scholar
• [ cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/byetta
   Google Scholar
• [ cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon
   Google Scholar
• [ cited 2020 May 22]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity
   Google Scholar
• [ cited 2020 May 22]. Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
   Google Scholar
• Dhillon S. Semaglutide: first global approval. Drugs. 2018;78(2):275–284.
   PubMed Web of Science ®Google Scholar
• Jensen L, Helleberg H, Roffel A, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2017;104:31–41.
   PubMed Web of Science ®Google Scholar
• Marbury TC, Flint A, Jacobsen JB, et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381–1390.
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al.. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. DOI:10.1111/dom.12932.
   PubMed Web of Science ®Google Scholar
• Kapitza C, Nosek L, Jensen L, et al.. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497–504.
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schaffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. DOI:10.1021/acs.jmedchem.5b00726.
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide) [prescribing information]. Bagsvaerd: Novo Nordisk; 2017 [cited 2020 May 22]. Available from: http://www.novo-pi.com/victoza.pdf
   Google Scholar
• Trulicity (dulaglutide) [prescribing information]. Indianapolis: Eli Lily and Company; 2017 [cited 2020 May 22]. Available from: http://pi.lilly.com/us/trulicity-uspi.pdf
   Google Scholar
• Gedulin BR, Smith PA, Jodka CM, et al.. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356(1–2):231–238. DOI:10.1016/j.ijpharm.2008.01.015.
   PubMedGoogle Scholar
• Nauck MA, Petrie JR, Sesti G, et al.. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016 Feb;39(2):231–241. DOI:10.2337/dc15-0165.
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Steen O. Semaglutide: review and place in therapy for adults with type 2 Diabetes. Can J Diabetes. 2019 Mar;43(2):136–145. DOI:10.1016/j.jcjd.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al.. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. DOI:10.2337/dc17-0417.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al.. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. DOI:10.1016/S2213-8587(18)30024-X.
   PubMed Web of Science ®Google Scholar
• Smits MM, Tonneijck L, Muskiet MH, et al.. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017 Jan;176(1):77–86. DOI:10.1530/EJE-16-0507.
   PubMed Web of Science ®Google Scholar
• Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126–5134.
   PubMed Web of Science ®Google Scholar
• Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services. Washington, DC: FDA/Center for Drug Evaluation; 2008. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf
   Google Scholar
• Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. DOI:10.1056/NEJMoa1607141.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al.. EXSCEL study group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017 Sep 28;377(13):1228–1239. DOI:10.1056/NEJMoa1612917.
   PubMed Web of Science ®Google Scholar
• Kalra S, John M, Unnikrishnan AG. Glycemic equipoise. Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):18–20. DOI:10.4103/2230-8210.194361.
   PubMedGoogle Scholar
• Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020;9:947.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al.. update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2019;63:221–228. (2020). DOI:10.1007/s00125-019-05039-w.
   Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al.. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 Aug 31;ehz486. DOI:10.1093/eurheartj/ehz486.
   Web of Science ®Google Scholar
• Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19–28.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Bain SC, Leiter LA, et al.. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018 Apr;20(4):889–897. DOI:10.1111/dom.13172.
   PubMed Web of Science ®Google Scholar
• Bain SC, Klufas MA, Ho A, et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab. 2019 Mar;21(3):454–466. DOI:10.1111/dom.13538.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al.. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121–130. DOI:10.1016/S0140-6736(19)31149-3.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Catarig AM, Frias JP, et al.. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834–844. DOI:10.1016/S2213-8587(19)30311-0.
   PubMed Web of Science ®Google Scholar
• Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367.
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al.. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2019 Sep 17;101117. DOI:10.1016/j.diabet.2019.101117.
   Web of Science ®Google Scholar
• Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:2255–2263.
   PubMed Web of Science ®Google Scholar
• Study F. Study to see how Semaglutide works compared to placebo in people with Type 2 Diabetes and Chronic kidney disease (FLOW). ClinicalTrials.gov identifyer: NCT0383; 1915.
   Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486.
   PubMed Web of Science ®Google Scholar
• Monami M, Nreu B, Scatena A, et al.. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017 Sep;19(9):1233–1241. DOI:10.1111/dom.12926.
   PubMed Web of Science ®Google Scholar
• [ cited 2020 May 22]. Available from: https://assets.publishing.service.gov.uk/media/59f081c6e5274a18bc07411b/Eperzan_Letter_-_090917.pdf
   Google Scholar
• Boye KS, Matza LS, Stewart KD, et al.. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J Med Econ. 2019 Aug;22(8):806–813. DOI:10.1080/13696998.2019.1609482.
   PubMed Web of Science ®Google Scholar
• Viljoen A, Hoxer CS, Johansen P, et al.. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2019 Mar;21(3):611–621. DOI:10.1111/dom.13564.
   PubMed Web of Science ®Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al.. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–1470. DOI:10.1001/jama.2017.14752.
   PubMed Web of Science ®Google Scholar
• Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10:eaar7047.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al.. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019. DOI:10.2337/dc19-0883.
   Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet Lond Engl. 2019;394(10192):39–50.
   PubMed Web of Science ®Google Scholar
• Bain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499–508.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. DOI:10.1056/NEJMoa1901118.. .
   PubMed Web of Science ®Google Scholar
• [ cited 2020 May 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914326
   Google Scholar